HAVN Life Sciences Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- HAVN Life Sciences Inc. HAVN Life Sciences Inc. is a biotechnology company focused on the research, development, and standardized extraction of psychopharmacological products derived from plants and fungi. The company pursues the creation of active pharmaceutical ingredients (APIs), natural health products, and innovative therapies to support brain health, cognitive function, and mental wellness; its core offerings include standardized psychedelic compounds such as psilocybin, psilocin, and baeocystin from Psilocybe spp. mushrooms, alongside high-quality mushroom and plant extracts designed to boost immune function, reduce inflammation, enhance memory and brain function, support energy levels, and mitigate stress through formulations like Mind Mushroom, Bacopa Brain, and Rhodiola Relief. Through its research division, HAVN Labs, it develops an end-to-end supply chain for naturally derived psychedelic compounds targeted at clinical researchers and serves patient markets in Canada with technology-focused, data-driven psychedelic therapies. Founded in 2020 and headquartered at 605-130 Brew Street in Port Moody, British Columbia, Canada, the company operates primarily in the healthcare and biotechnology sectors, with a focus on North American markets including e-commerce distribution via yourhavnlife.com. Recent developments include a November 2023 cease trade order from the British Columbia Securities Commission due to failure to file financial statements, ongoing bi-weekly management cease trade order status updates as of 2023, a terminated 2022 amalgamation agreement with Spore Life Sciences Inc. while retaining a secured convertible note interest, and prior operational updates on restructuring efforts and financing pursuits amid compliance challenges.
HAVN Life to Present at Upcoming LD Micro Invitational XII
HAVN Life Sciences Inc. to Present at the Planet MicroCap Showcase 2022 in Las Vegas on Wednesday, May 4, 2022
HAVN Life Announces Supply and Distribution MOU with Mycrodose Therapeutics
HAVN Life Announces Distribution Deal with Horizon Grocery + Wellness
HAVN Life Signs Agreement to Supply Psilocybin for Mycotopia Therapies
HAVN Life Harvests First Crop of Psilocybin Mushrooms at its Jamaica Facility
7 Stocks to Buy if You Think Alternative Therapies Are the Future
HAVN Life Signs Agreement to Enable Export of Psilocybin into Canada, the US and Europe
HAVN Life Signs Exclusive Supply Agreement With Cube Psytech
HAVN Life is Looking for a Safe Haven to Mental Health Through Psychedelic Medicine
HAVN Life Secures Production & Supply Agreement to Expand Retail Product Offerings
HAVN Life Enters into Agreement to Acquire Clinical Stage IP for Development of LSD-Derived API for Cluster Headaches
Havn Life CEO Tim Moore to Appear at Upcoming Q2 Investor SummitHavn Life CEO Tim Moore to Appear at Upcoming Q2 Investor Summit
Havn Life Signs Exclusive Supply Agreement with ATMA Journey Centers
Havn Labs Jamaica Facility Now Fully Operational
Havn Life Completes Acquisition of Strategic Manufacturing & Packaging Facility for its Retail Division
Havn Life Sciences Signs LOI to Research and Develop Medical Psilocybin with Jamaican Company Hypha Wellness
Havn Life CEO to Present at Zooming with LD, a Leading Platform for Microcap Companies